Plaintiff-appellant Jeffrey Goldstein contends that the prescription medication Remicade caused his pulmonary fibrosis, requiring a bilateral lung replacement. Goldstein appeals the magistrate judge’s exclusion of Dr. Douglas Pohl’s expert testimony on general causation, pursuant to Fed.R.Evid. 702 and Daubert v. Merrell Dow Pharmaceuticals, Inc., 509 U.S. 579, 113 S.Ct. 2786, 125 L.Ed.2d 469 (1993). We review a trial court’s Daubert rulings under an abuse of discretion standard; we must affirm such rulings unless the district court has made a “clear error of judgment” or applied an incorrect legal standard. McClain v. Metabolife Intern’l, Inc., 401 F.3d 1233, 1238 (11th Cir. 2005). Goldstein does not argue that the trial court applied an incorrect legal standard; instead, he alleges that the trial court clearly erred in finding that Dr. Pohl’s opinion with respect to general causation was not adequately supported by scientific studies and literature. After review of the record and the parties’ briefs and with the benefit of oral argument, we affirm.

Dr. Pohl did not rely on any epidemiological studies that connect Remicade with pulmonary fibrosis. This is not fatal, but makes his task to show general causation more difficult. See Rider v. Sandoz Pharmaceuticals Corp., 295 F.3d 1194, 1198 (11th Cir. 2002).

Instead, Dr. Pohl reviewed four sources to make his general causation assessment. The first category, plaintiffs lung and bowel pathology reports, is not relevant to general causation because it focuses on the plaintiff. See McClain, 401 F.3d at 1239 (“General causation is concerned with whether an agent increases the incidence of disease in a group and not whether the agent caused any given individual’s disease.”). The second category, MedWatch case reports submitted by doctors who observed possible reactions to Remicade but made without medical controls or scientific assessment, “may support other proof of causation, [but] alone ordinarily cannot prove causation.” Id. at 1199. 1 The third category, a review of medical textbooks, revealed no information. The fourth category, a review of abstracts of four articles linking Remicade with pulmonary fibrosis, is relevant to general causation but provides limited information.

“A court may conclude that there is simply too great an analytical gap between the data and the opinion proffered.” Gen *333 eral Elec. Co. v. Joiner, 522 U.S. 136, 146, 118 S.Ct. 512, 519, 139 L.Ed.2d 508 (1997) (citation omitted). The district court did so here, and we find no abuse of discretion in its determination. 2

AFFIRMED.